KR20060110304A - 칼시토닌 및 부갑상선 호르몬 치료 효능을 위한 바이오마커 - Google Patents

칼시토닌 및 부갑상선 호르몬 치료 효능을 위한 바이오마커 Download PDF

Info

Publication number
KR20060110304A
KR20060110304A KR1020067010205A KR20067010205A KR20060110304A KR 20060110304 A KR20060110304 A KR 20060110304A KR 1020067010205 A KR1020067010205 A KR 1020067010205A KR 20067010205 A KR20067010205 A KR 20067010205A KR 20060110304 A KR20060110304 A KR 20060110304A
Authority
KR
South Korea
Prior art keywords
protein
kinase
alpha
type
gene expression
Prior art date
Application number
KR1020067010205A
Other languages
English (en)
Korean (ko)
Inventor
마리아 보바딜라
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20060110304A publication Critical patent/KR20060110304A/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020067010205A 2003-11-25 2004-11-24 칼시토닌 및 부갑상선 호르몬 치료 효능을 위한 바이오마커 KR20060110304A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52502503P 2003-11-25 2003-11-25
US60/525,025 2003-11-25

Publications (1)

Publication Number Publication Date
KR20060110304A true KR20060110304A (ko) 2006-10-24

Family

ID=34652293

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067010205A KR20060110304A (ko) 2003-11-25 2004-11-24 칼시토닌 및 부갑상선 호르몬 치료 효능을 위한 바이오마커

Country Status (12)

Country Link
US (1) US20070099828A1 (ru)
EP (1) EP1689427A1 (ru)
JP (1) JP2007522100A (ru)
KR (1) KR20060110304A (ru)
CN (1) CN1905894A (ru)
AU (1) AU2004294268A1 (ru)
BR (1) BRPI0416945A (ru)
CA (1) CA2546111A1 (ru)
IL (1) IL175575A0 (ru)
MX (1) MXPA06005950A (ru)
RU (1) RU2006122632A (ru)
WO (1) WO2005053731A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043393A1 (en) * 2008-10-17 2010-04-22 Roche Diagnostics Gmbh Use of biglycan in the assessment of heart failure
CA2779730C (en) 2009-11-05 2019-04-30 University Of Virginia Patent Foundation Compositions and methods for detecting plectin-1 as a biomarker for cancer
WO2012125914A1 (en) * 2011-03-16 2012-09-20 University Of Delaware Injectable delivery system for heparan sulfate binding growth factors
CN112748241B (zh) * 2019-10-16 2024-05-31 浙江中医药大学附属第二医院 一种用于检测i型骨质疏松症的蛋白芯片及其制作方法与应用
CN112574991B (zh) * 2020-12-17 2023-03-17 安徽师范大学 一种寡核苷酸、载体及制备方法和应用
CN116173187B (zh) * 2023-03-14 2024-05-10 哈尔滨医科大学 降钙素在制备防治支架内再狭窄药物中的应用、药物涂层支架及制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175437A (ja) * 1983-03-25 1984-10-04 Teikoku Hormone Mfg Co Ltd 高コレステロ−ル血症改善剤
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US5514365A (en) * 1988-10-11 1996-05-07 Schiapparelli Salute S.P.A. Pharmaceutical compositions comprising calcitonin for intranasal administration
JPH02229119A (ja) * 1989-02-28 1990-09-11 Toyo Jozo Co Ltd 動脈硬化予防および治療剤
WO2002024943A2 (en) * 2000-09-19 2002-03-28 Curagen Corporation Method of identifying osteoregenerative agents using differential gene expression
BR0209646A (pt) * 2001-05-16 2006-10-10 Novartis Ag genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos
US7384736B2 (en) * 2001-09-06 2008-06-10 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
BR0213958A (pt) * 2001-10-31 2004-09-08 Novartis Ag Métodos para tratar diabete e condições relacionadas com base em polimorfismos no gene tcf1

Also Published As

Publication number Publication date
WO2005053731A1 (en) 2005-06-16
CN1905894A (zh) 2007-01-31
US20070099828A1 (en) 2007-05-03
JP2007522100A (ja) 2007-08-09
MXPA06005950A (es) 2006-07-06
RU2006122632A (ru) 2008-02-10
EP1689427A1 (en) 2006-08-16
CA2546111A1 (en) 2005-06-16
BRPI0416945A (pt) 2007-02-13
IL175575A0 (en) 2006-09-05
AU2004294268A1 (en) 2005-06-16

Similar Documents

Publication Publication Date Title
Gelse et al. Molecular differentiation between osteophytic and articular cartilage–clues for a transient and permanent chondrocyte phenotype
Reppe et al. Eight genes are highly associated with BMD variation in postmenopausal Caucasian women
Arici et al. Transforming growth factor-β3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation
Schmidt et al. Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats
Reinholz et al. Differential gene expression of TGF-β family members and osteopontin in breast tumor tissue: analysis by real-time quantitative PCR
Yang et al. Evidence of impaired adipogenesis in insulin resistance
Chabrolle et al. Adiponectin increases insulin-like growth factor I-induced progesterone and estradiol secretion in human granulosa cells
Olney et al. Growth factor regulation of human growth plate chondrocyte proliferation in vitro
Yakar et al. Circulating levels of IGF-1 directly regulate bone growth and density
NAKATANI et al. Tissue-specific expression of four insulin-like growth factor-binding proteins (1, 2, 3, and 4) in the rat ovary
Trošt et al. A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts
WO2008060156A1 (en) Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
JP2007197455A (ja) 骨疾患を処置するための骨形成タンパク質
Conover et al. Regulation of pregnancy-associated plasma protein-A expression in cultured human osteoblasts
Barreca et al. Intrafollicular insulin-like growth factor-II levels in normally ovulating women and in patients with polycystic ovary syndrome
Voge et al. Quantification of insulin-like growth factor binding protein mRNA using real-time PCR in bovine granulosa and theca cells: effect of estradiol, insulin, and gonadotropins
Zajac et al. Identification of calcitonin and calcitonin gene-related peptide messenger ribonucleic acid in medullary thyroid carcinomas by hybridization histochemistry
Harlow et al. Lysyl oxidase gene expression and enzyme activity in the rat ovary: regulation by follicle-stimulating hormone, androgen, and transforming growth factor-β superfamily members in vitro
Hattori et al. Spontaneous growth hormone (GH) secretion by unstimulated human lymphocytes and the effects of GH-releasing hormone and somatostatin
Hong et al. Cytokine regulation of gingival fibroblast lysyl oxidase, collagen, and elastin
Friedl et al. Intermittent parathyroid hormone (PTH) treatment and age‐dependent effects on rat cancellous bone and mineral metabolism
KR20060110304A (ko) 칼시토닌 및 부갑상선 호르몬 치료 효능을 위한 바이오마커
Bail et al. Systemic application of growth hormone enhances the early healing phase of osteochondral defects—a preliminary study in micropigs
JP5118851B2 (ja) 線維芽細胞増殖因子フラグメントの使用
Zhao et al. Matrix Gla protein gene expression is induced by transforming growth factor-beta in embryonic lung culture

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid